For research use only. Not for therapeutic Use.
LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease[1][2].
LY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a single oral dose with a maximum EO of greater than 90% in rat[1].
| Catalog Number | I044043 |
| CAS Number | 2241514-56-5 |
| Synonyms | N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide |
| Molecular Formula | C16H22FN5O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)/t9-,12-/m0/s1 |
| InChIKey | FRVXHWNHGWUTQO-CABZTGNLSA-N |
| SMILES | CC1CC(CCN1CC2=C(N=C(S2)NC(=O)C)F)OCC3=NOC(=N3)C |
| Reference | [1]. Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer’s & Dementia. 07 December 2020 . [2]. Nicolas Jacques Francois Dreyfus, et al. N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. Patent WO2018140299A1. |
